Contribute Try STAT+ Today

It’s been just over a month since Amgen and Novartis ended two studies of an experimental Alzheimer’s treatment early, the latest in a long string of failures in Alzheimer’s drug development.

There is still no effective treatment for the disease. But as the population ages, the already significant need for an Alzheimer’s treatment is only growing more urgent, said Dr. David Reese, executive vice president of research and development at Amgen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • A new study (21 Aug 2019) finds that “removing brain immune cells known as microglia from rodent models of Alzheimer’s disease, beta-amyloid plaques – the hallmark pathology of AD – never formed.”

    Link between brain immune cells and Alzheimer’s disease development identified

    Meanwhile, in another recent study making waves, “In vitro data revealed that gal3 was required to fully activate microglia in response to fibrillar Aβ”

    This raises the question whether beta-amyloid plaques accumulate in a self-reinforcing feedback cycle that is dependent upon Galectin-3 activation of microglia.

    Galectin-3 inhibition should be investigated, for example GR-MD-02 (belapectin) which is currently entering Phase 3 for advanced NASH fibrosis. There appears to be a common mechanism between inflammation and fibrosis of other organs and of AD.

Comments are closed.